Burning Rock Biotech (FRA:6BU0) Tariff Resilience Score: 4/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6BU0 Burning Rock Biotech Ltd FRA:6BU0
63 GF Score
Price €7.40
GF Value €5.72
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Tariff Resilience Score?

Burning Rock Biotech FRA:6BU0 -11.90% 63 Tariff Resilience Score is 4 as of Jul. 17, 2026. GuruFocus rates FRA:6BU0 with a GF Score™ of 63/100 and a GF Value™ of €5.72 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 69.63% on this metric.

Burning Rock Biotech has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Burning Rock Biotech has Burning Rock Biotech, operating in the biotech sector, faces tariff risks due to its reliance on international supply chains for equipment and materials. The company has limited pricing power and few alternative suppliers, increasing its vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Burning Rock Biotech might have Average Resilient.

Burning Rock Biotech  (FRA:6BU0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Burning Rock Biotech Tariff Resilience Score Related Terms

FRA:6BU0 vs XGN, IDXG, PRPO: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Burning Rock Biotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Tariff Resilience Score falls into.


FRA:6BU0
63GF Score
Burning Rock Biotech Ltd FRA:6BU0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Burning Rock Biotech (FRA:6BU0) has a Tariff Resilience Score of 4 as of Jul. 17, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Burning Rock Biotech ranks #65 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 30.4%.
Is Burning Rock Biotech's Tariff Resilience Score too high?
Burning Rock Biotech's current Tariff Resilience Score is 4. Based on the distribution chart, Burning Rock Biotech ranks #65 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Tariff Resilience Score compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #65 out of 214 companies for Tariff Resilience Score. This puts Burning Rock Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Burning Rock Biotech's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.72, compared to a current price of €7.40 — trading 29.4% above its estimated fair value. The current Tariff Resilience Score is 4. Burning Rock Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Tariff Resilience Score is 4 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of €7.40 is trading 29.4% above its estimated GF Value™ of €5.72. GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.

Key valuation signals for FRA:6BU0:

  • Tariff Resilience Score: 4
  • GF Value™: €5.72 vs. price of €7.40 (29.4% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges BNR:USA
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
63GF Score

Get the complete analysis for FRA:6BU0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.40
Price
€5.72
GF Value